Document is current
Any future updates will be listed below
-
Authors
Elsharkasy, Omnia M.
Hegeman, Charlotte V. https://orcid.org/0000-0002-7095-8834
Driedonks, Tom A. P. https://orcid.org/0000-0003-0928-9712
Liang, Xiuming https://orcid.org/0000-0003-0202-1211
Lansweers, Ivana
Cotugno, Olaf L.
de Groot, Ingmar Y.
de Wit, Zoë E. M. N. J.
Garcia-Guerra, Antonio
Moorman, Niels J. A.
Boonstra, Sjoerd H.
Bosman, Esmeralda D. C.
Lefferts, Juliet W.
de Voogt, Willemijn S. https://orcid.org/0009-0008-7876-5018
François, Jerney J.
van Wesel, Annet C. W.
El Andaloussi, Samir https://orcid.org/0000-0003-4468-9113
Schiffelers, Raymond M. https://orcid.org/0009-0004-2423-209X
Kooijmans, Sander A. A. https://orcid.org/0000-0002-8893-9578
Mastrobattista, Enrico https://orcid.org/0000-0002-6745-2015
Vader, Pieter https://orcid.org/0000-0002-7059-8920
de Jong, Olivier G. https://orcid.org/0000-0002-5952-9617
-
Funding
Funding for this research was provided by:
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (VI.Veni.192.174)
- License Information
-
More Information
Article History
Received: 12 June 2024
Accepted: 24 October 2025
First Online: 21 November 2025
Competing interests
: O.G.d.J. is on the advisory board of The Organoid Company, Rotterdam, The Netherlands. S.E.A. is a consultant and stakeholder in Evox Therapeutics Limited, Oxford, United Kingdom. The remaining authors declare no competing interests.
